Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi · 2010
[Safety and epidemiological effects of the first China-made mass A (H1N1) influenza vaccination].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ji Wen-yan, Lu Li, Lü Min, Miao Liang, Gao Ting, Huang Ruo-gang, Suo Luo-dan, Liu Dong-lei, Ma Rui, Yu Rui, Zhangzhu Jia-zi, Liu Wei-xiang, Zeng Yang, Li Xiao-mei, Wu Jiang
Аннотация
OBJECTIVE: To evaluate the safety and epidemiological effects on the first mass vaccination program, using the China-made A (H1N1) influenza vaccine.
METHODS: Descriptive epidemiology and cohort study design were used to assess the influenza A H1N1 vaccine on its safety and epidemiological effects.
RESULTS: 95 244 subjects were immunized with A (H1N1) influenza vaccine. 193 adverse events were reported through AEFI Management System, with the Reported rates of AEFI as 2.03‰. Most of the adverse events (137/193, 71.0%) happened during the first 24 hours after immunization was carried out. Of 81 adverse reactions confirmed to be related to immunization, with 78 (96.3%) showed mild reactions. No Guillain-Barre Syndrome related to vaccination was reported through the AEFI Management System. The epidemiological protection rate of A (H1N1) vaccine could reach 80.9% when the coverage was not considered.
CONCLUSION: The A (H1N1) influenza vaccine showed a similar safety profile to seasonal flu vaccine. The vaccine demonstrated a good epidemiological effects against A (H1N1) influenza virus infection.
METHODS: Descriptive epidemiology and cohort study design were used to assess the influenza A H1N1 vaccine on its safety and epidemiological effects.
RESULTS: 95 244 subjects were immunized with A (H1N1) influenza vaccine. 193 adverse events were reported through AEFI Management System, with the Reported rates of AEFI as 2.03‰. Most of the adverse events (137/193, 71.0%) happened during the first 24 hours after immunization was carried out. Of 81 adverse reactions confirmed to be related to immunization, with 78 (96.3%) showed mild reactions. No Guillain-Barre Syndrome related to vaccination was reported through the AEFI Management System. The epidemiological protection rate of A (H1N1) vaccine could reach 80.9% when the coverage was not considered.
CONCLUSION: The A (H1N1) influenza vaccine showed a similar safety profile to seasonal flu vaccine. The vaccine demonstrated a good epidemiological effects against A (H1N1) influenza virus infection.